Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes

IF 20.4 1区生物学 Q1 INFECTIOUS DISEASES Lancet Microbe Pub Date : 2025-07-01 Epub Date: 2025-03-15 DOI:10.1016/j.lanmic.2025.101117

Tom A Yates , Daniel J Grint

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

建立新的结核病治疗方案的3期非劣效性试验的主要疗效终点应仅包括微生物结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Lancet Microbe Multiple-

CiteScore

27.20

自引率

0.80%

发文量

278

审稿时长

6 weeks

期刊介绍： The Lancet Microbe is a gold open access journal committed to publishing content relevant to clinical microbiologists worldwide, with a focus on studies that advance clinical understanding, challenge the status quo, and advocate change in health policy.

期刊最新文献

Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study. Understanding the cervicovaginal immune response to Lactobacillus crispatus CTV-05. Understanding the cervicovaginal immune response to Lactobacillus crispatus CTV-05. Nipah virus outbreaks in south Asia. Vaginal microbiota transplantation for treatment of vaginal dysbiosis without the use of antibiotics: a double-blind, randomised controlled trial in women with vaginal dysbiosis.